Compare INTZ & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | KTTA |
|---|---|---|
| Founded | 1983 | 2020 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 18.1M |
| IPO Year | 2020 | N/A |
| Metric | INTZ | KTTA |
|---|---|---|
| Price | $0.95 | $0.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.75 | $3.00 |
| AVG Volume (30 Days) | 141.2K | ★ 323.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,015,000.00 | N/A |
| Revenue This Year | $25.34 | N/A |
| Revenue Next Year | $14.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.66 | $0.28 |
| 52 Week High | $2.64 | $2.06 |
| Indicator | INTZ | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 33.88 |
| Support Level | $0.72 | $0.51 |
| Resistance Level | $1.17 | $0.80 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 59.25 | 35.26 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.